pDONR223-BRD3 Citations (1)
Originally described in: COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA Nature. 2010 Dec 16;468(7326):968-72. doi: 10.1038/nature09627 PubMed Journal
Articles Citing pDONR223-BRD3
| Articles |
|---|
| Dexmedetomidine attenuation of renal ischaemia-reperfusion injury requires sirtuin 3 activation. Si Y, Bao H, Han L, Chen L, Zeng L, Jing L, Xing Y, Geng Y. Br J Anaesth. 2018 Dec;121(6):1260-1271. doi: 10.1016/j.bja.2018.07.007. Epub 2018 Sep 15. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.